Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5′-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018;67(1):7–30. doi:10.3322/caac.21387.
   Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22. doi:10.1038/nrc2982. PMID:21160525
   PubMed Web of Science ®Google Scholar
• Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor,gender, and smoking. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S109–11.
   PubMed Web of Science ®Google Scholar
• Kofler B, Laban S, Busch CJ, Lörincz B, Knecht R. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol. 2014;271(7):1861–7. doi:10.1007/s00405-013-2603-0. PMID:23934317
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Eng J Med. 2016;375(19):1856–67. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016;34(32):3838–45. doi:10.1200/JCO.2016.68.1478.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65. doi:10.1016/S1470-2045(16)30066-3. PMID:27247226.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. pembrolizumab (KEYTRUDA). Silver Spring (MD): U.S. Food and Drug Administration; 2016 Aug 09 [accessed 2018 Feb 02]. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm515627.htm
   Google Scholar
• Ma SR, Deng WW, Liu JF, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ. Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer. 2017;16(1):99. doi:10.1186/s12943-017-0665-0. PMID:28592285.
   PubMedGoogle Scholar
• Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. Am Soc Clin Oncol Educ Book.2016;35:e450–8.
   PubMedGoogle Scholar
• Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal. 2013;9(2):145–65. doi:10.1007/s11302-012-9349-9. PMID:23271562.
   PubMed Web of Science ®Google Scholar
• Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T-cells. Blood. 2008;111(1):251–9. doi:10.1182/blood-2007-03-081646. PMID:17909080.
   PubMed Web of Science ®Google Scholar
• Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, et al. A2A adenosine receptor protects tumors from antitumor T-cells. Proc Natl Acad Sci U S A. 2006;103(35):13132–7. doi:10.1073/pnas.0605251103.
   PubMed Web of Science ®Google Scholar
• Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia SJ. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013;14(9):860–8. doi:10.4161/cbt.25643.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Sougnez C, Lichtenstein L, Cibulskis K, Lander E, Gabriel SB, Getz G, Ally A, Balasundaram M, Birol I, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82. doi:10.1038/nature14129. PMID:25631445.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7. PMID:27549193.
   PubMed Web of Science ®Google Scholar
• Ikawa T, Masuda K, Endo TA, Endo M, Isono K, Koseki Y, Nakagawa R, Kometani K, Takano J, Agata Y, et. al. Conversion of T cells to B cells by inactivation of polycomb-mediated epigenetic suppression of the B-lineage program. Genes Dev. 2016;30(22):2475–85. doi:10.1101/gad.290593.116. PMID:27913604.
   PubMed Web of Science ®Google Scholar
• Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, Carter R, Awad W, Neale G, Thomas PG, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017;170(1):142–57. doi:10.1016/j.cell.2017.06.007. PMID:28648661.
   PubMed Web of Science ®Google Scholar
• McPherson RC, Konkel JE, Prendergast CT, Thomson JP, Ottaviano R, Leech MD, Kay O, Zandee Se, Sweenie CH, Wraith DC, et. al. Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy. Elife. 2014;3. doi:10.7554/eLife.03416.
   Web of Science ®Google Scholar
• Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, Wei Z, Lu P, Austin JW, Riley JL, et. al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 2011;35(3):400–12. doi:10.1016/j.immuni.2011.06.015. PMID:21943489.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Grünen S, Dietrich J, Kristiansen G, Landsberg J, Dietrich D. PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia. Leukemia. 2017;31(3):738–43. doi:10.1038/leu.2016.328. PMID:27840427.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Dietrich J, Dietrich D. PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology. 2016;6(1):e1257454. doi:10.1080/2162402X.2016.1257454. PMID:28197377.
   PubMed Web of Science ®Google Scholar
• Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G. PD-L1 promoter methylation isa prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016;7(48):79943–55. doi:10.18632/oncotarget.13161. PMID:27835597.
   PubMedGoogle Scholar
• Goltz D, Gevensleben H, Dietrich J, Schroeck F, de Vos L, Droege F, Kristiansen G, Schroeck A, Landsberg J, Bootz F, et al. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget. 2017;8(25):41011–20. doi:10.18632/oncotarget.17354. PMID:28487502.
   PubMedGoogle Scholar
• Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop Ja, et. al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–41. doi:10.1158/0008-5472.CAN-12-2384. PMID:23288508.
   PubMed Web of Science ®Google Scholar
• Lechner M, Fenton TR. The Genomics, Epigenomics, and Transcriptoms of HPV-Associated Oropharyngeal Cancer – Understanding the Basis of a Rapidly Evolving Disease. Adv Genet. 2016;93:1–56. PMID:26915269.
   PubMed Web of Science ®Google Scholar
• Brennan K, Koenig JL, Gentles AJ, Sunwoo JB, Gevaert O. Identification of an atypical etiological head and neck squamous carcinoma subtype featuring the CpG island methylator phenotype. EBioMedicine. 2017;17:223–36. doi:10.1016/j.ebiom.2017.02.025. PMID:28314692.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632–41. doi:10.1158/1078-0432.CCR-13-3310. PMID:25056374.
   PubMed Web of Science ®Google Scholar
• Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer. 2018;91:47–55. doi:10.1016/j.ejca.2017.12.016. PMID:29331751.
   PubMed Web of Science ®Google Scholar
• Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, et al. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016;22(12):2939–49. doi:10.1158/1078-0432.CCR-15-2314. PMID:26763254.
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, West J, Beck S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum Mol Genet. 2013;22(R1):R7–R15. doi:10.1093/hmg/ddt375. PMID:23918660.
   PubMed Web of Science ®Google Scholar
• Yuan T, Jiao Y, de Jong S, Ophoff RA, Beck S, Teschendorrf AE. An integrative multi-scale analysis of the dynamic DNA methylation landscape in aging. PLoS Genet. 2015;11(2):e1004996. doi:10.1371/journal.pgen.1004996. PMID:25692570.
   PubMed Web of Science ®Google Scholar
• Rakyan VK, Down TA, Maslau S, Andrew T, Yang TP, Beyan H, Whittaker P, McCann OT, Finer S, Valdes AM, et al. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin. Genome Res. 2010;20(4):434–9. doi:10.1101/gr.103101.109. PMID:20219945.
   PubMed Web of Science ®Google Scholar
• Zhao M, Qin J, Yin H, Tan Y, Liao W, Liu Q, Luo S, He M, Liang G, Shi y, et al. Distinct epigenomes in CD4+ T cells of newborns, middle-ages and centenarians. Sci Rep. 2016;6:38411. doi:10.1038/srep38411. PMID:27917918.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim K, Kim H, Yoon G, Lee K. Characterization of age signatures of DNA methylation in normal and cancer tissues from multiple studies. BMC Genomics. 2014;15:997. doi:10.1186/1471-2164-15-997. PMID:25406591.
   PubMed Web of Science ®Google Scholar
• Acevedo N, Reinius LE, Vitezic M, Fortino V, Söderhäll C, Honkanen H, Veijola R, Simell O, Toppari J, Ilonen J, et al. Age-associated DNA methylation changes in immune genes, histone modifiers and chromatin remodeling factors within 5 years after birth in human blood leukocytes. Clin Epigenetics. 2015;7:34. doi:10.1186/s13148-015-0064-6. PMID:25874017.
   PubMed Web of Science ®Google Scholar
• Dozmorov MG, Coit P, Maksimowicz-McKinnon K, Sawalha AH. Age-associated DNA methylation changes in naïve CD4+ T cells suggest an evolving autoimmune epigenotype in aging T cells. Epigenomics. 2017;9(4):429–45. doi:10.2217/epi-2016-0143. PMID:28322571.
   PubMed Web of Science ®Google Scholar
• Fong L, Forde PM, Powderly JD, Goldman JW, Nemunaitis JJ, Luke JJ, Hellmann MD, Kummar S, Doebele RC, Mahadevan D, et al. Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. Abstract presented at: 2017 ASCO Annual Meeting; J Clin Oncol 35,2017 (suppl; abstr 3004); doi:10.1200/JCO.2017.35.15_suppl.3004. 2017 Jun 5; Chicago, Illinois, USA.
   Google Scholar
• Innate Pharma. IPH53: Anti-CD73 Checkpoint Inhibitor Program. Marseille (France): Innate Pharma SA; 2017 Nov 16 [accessed 2018 Feb 02].
   Google Scholar
• Lechner M, Fenton T, West J, Wilson G, Feber A, Henderson S, Thrilwell C, Dibra HK, Jay A, Butcher L, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 2013;5(2):15. doi:10.1186/gm419. PMID:23419152.
   PubMedGoogle Scholar
• Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, Drummond H, IBD BIOM consortium, IBD CHARACTER consortium, Wilson DC, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nat Commun. 2016;7:13507. doi:10.1038/ncomms13507. PMID:27886173.
   PubMed Web of Science ®Google Scholar
• Mamrut S, Avidan N, Staun-Ram E, Ginzburg E, Truffault F, Berrih-Aknin S, Miller A. Integrative analysis of methylome and transcriptome in human blood identifies extensive sex and immune cell-specific differentially methylated regions. Epigenetics. 2015;10(10):943–57. doi:10.1080/15592294.2015.1084462. PMID:26291385.
   PubMed Web of Science ®Google Scholar
• Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell population. PLoS Genet. 2013;9(8):e1003678. doi:10.1371/journal.pgen.1003678. PMID:23950730.
   PubMed Web of Science ®Google Scholar